Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: A subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study

Journal of the American Geriatrics Society

Volumn 55, Issue 7, 2007, Pages 1015-1022

  Ye, Ping ^a   Lu, Zong Liang ^b   Du, Bao Min ^b   Chen, Zuo ^b   Wu, Yang Feng ^b   Yu, Xue Hai ^b   Zhao, Yu Cheng ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Coronary heart disease; Elderly; Statin; Xuezhikang

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUEZHIKANG;

AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER; CAUSE OF DEATH; CHINESE MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY RISK; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYALGIA; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TREATMENT OUTCOME;

AGE FACTORS; AGED; CAUSE OF DEATH; CHINA; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; MORTALITY; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34347404879     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01230.x     Document Type: Article

References (21)

1. Hennekens CH. Increasing burden of cardiovascular disease: Current knowledge and future direction for research on risk factors. Circulation 1998 97 : 1095 1102.
2. Uemura K. International trends in cardiovascular diseases in the elderly. Eur Heart J 1988 95 (Suppl D) : 1 8.
3. Kronmal RA, Cain KC, Ye Z et al. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993 153 : 1065 1073.
4. Castelli WP, Wilson PW, Levy D et al. Cardiovascular risk factors in the elderly. Am J Cardiol 1989 63 : 12H 19H.
5. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999 282 : 2340 2346.
6. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996 335 : 1001 1009.
7. Xie S, Duan Z. Xuezhikang capsule regulates blood lipids with high efficacy: An overview of its preparation, pharmacology, toxicology, and results of clinical trials. Chin Med News 1996 11 : 13 14.
8. Heber D, Yip I, Ashley JM et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999 69 : 231 236.
9. Mak KH, Ching CK, and for Lipascor investigator et al. A randomised, parallel, double-blind study comparing the lipid lowering effect of xuezhikang (Lipascor) with simvastatin in asymptomatic patients with hypercholesterolaemia. ASEAN Heart J 2005 13 : 15 20.
10. Lu ZL. Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang. China Coronary Secondary Prevention Study (CCSPS). Zhonghua Xin Xue Guan Bing Za Zhi 2005 33 : 109 115.
11. Miettinen TA, Pyorala K, Olsson AG et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997 96 : 4211 4218.
12. Hunt D, Young P et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001 134 : 931 940.
13. Shepherd J, Blauw GJ et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet 2002 360 : 1623 1630.
14. Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomized controlled trial. Lancet 2006 368 : 1155 1163.
15. Lee E, Ryan S, Birmingham B et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005 78 : 330 341.
16. Li JJ, Hu SS, Fang CH et al. Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: A short-term time course study in patients with stable angina. Clin Chim Acta 2005 352 : 217 224.
17. Zhao SP, Liu L, Cheng YC et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004 110 : 915 920.
18. BJerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001 110 : 716 723.
19. Dale KM, Coleman CI, Henyan NN et al. Statins and cancer risk: A meta-analysis. JAMA 2006 295 : 74 80.
20. Su NW, Lin YL, Lee MH et al. Ankaflavin from Monascus-fermented red rice exhibits selective cytotoxic effect and induces cell death on Hep G2 cells. J Agric Food Chem 2005 53 : 1949 1954.
21. Bogsrud MP, Ose L, Langslet G et al. The effect of red yeast rice on lipids, inflammatory markers and plasma glucose in subjects with mild hypercholesterolemia and mildly elevated plasma glucose. Atherosclerosis 2006 7 (Suppl 3) : 551 (abstract).